Roivant Sciences Ltd. ROIV
No buyback or stock pay figures in its 10-K data yet
XBRL, 10-KCash runway
Cash on the balance sheet of Sep 30, 2026 against the operating cash it used over the last four quarters · XBRL
Shown only when operating cash flow of the last twelve months is negative. A fact about the past twelve months, not a forecast: the company can raise money, cut costs or change pace. Debt due is on the Debt tab; share sales are in the dilution card below.
New shares against shares bought back
Dilution: new shares, stock pay and buybacks · S-3 and 424B, 3 years; 10-K
Shares offered
Since Nov 17, 2023: 1 shelf registration.
- Oct 3, 2025 Shelf registration: shares and other securities, amount not fixed S-3ASR
Every offering filing“Under this shelf registration statement, we or any selling securityholder may, from time to time, offer and sell in one or more offerings Common Shares, preference shares, various series of debt securities, warrants to purchase any of such securities and/or units either individually or in combination with other securities.”
S-3ASR, Oct 3, 2025
Paid in stock and bought back
No stock pay or buyback lines in the 10-K XBRL.
Where the cash came from and where it went
FY2026, from the cash flow statement in the 10-K, added up
The same cash, step by step
Came from
| Cash on hand used | $1.3B |
Went to
| Operating cash flow (outflow) | $750.3M |
| Capital spending | $8.2M |
| Other, net investments bought and sold, other financing and investing lines, and exchange rates |
$536.1M |
Each number is a line of the cash flow statement as the company tagged it. "Other, net" is what those lines do not cover (investments bought and sold, other financing and investing lines, and exchange rates); Tickdelta does not estimate it.
Where the operating cash went, year by year
FY2021 to FY2026 · cash flow statements, 10-K XBRL
| Fiscal year | Operating cash | Capital spending | Buybacks |
|---|---|---|---|
| Mar 31, 2026 | -$750.3M | $8.2M | - |
| Mar 31, 2025 | -$839.5M | $4.6M | $1.3B |
| Mar 31, 2024 | -$765.3M | $1.4M | - |
| Mar 31, 2023 | -$843.4M | $12.7M | - |
| Mar 31, 2022 | -$677.7M | $17.4M | - |
| Mar 31, 2021 | -$552.1M | $5.8M | - |
| Added up | -$4.4B | $50.1M | $1.3B |
Each bar is one fiscal year; its colours add up to what the cash flow statement says the company spent on each line, and the line across it is that year's operating cash flow. Spending above the line was paid from new debt, shares sold or cash on hand. A bar part links to the 10-K it comes from. A line the company did not report is left out, not estimated, so the shares are of operating cash only and can add up to more or less than 100%. Debt repaid is the gross amount, so refinanced debt is counted each time it is repaid. A reading aid, not a grade: Tickdelta does not say whether a split was good. Banks and insurers are left out.
Buybacks, dividends and share count
Year by year · XBRL, each 10-K
No buyback or share count data in the 10-K XBRL.
Buybacks month by month, and what is left to buy
Share buybacks · 10-Q, Part II Item 2, latest 4 quarters
“As of September 30, 2026, approximately $609.3 million remains available for share repurchases.”
10-Q, Part II Item 2
“On June 25, 2025, we announced that our board of directors had authorized up to $500 million (excluding fees and expenses) in common share repurchases.”
10-Q, Part II Item 2
Spent each month (shares × average price)
| Month | Shares bought | Average price |
|---|---|---|
| Aug 2026 | 939,193 | $35.76 |
| Jul 2026 | 1,114,659 | $34.88 |
| Jun 2026 | 2,062,317 | $28.83 |
| May 2026 | 1,690,967 | $28.64 |
| Apr 2026 | 3,552,362 | $28.34 |
Shares and average price are the numbers in the 10-Q table, row by row; "shares × price" is our multiplication of the two. A row with a price of "-" is an accelerated repurchase paid up front, where the 10-Q does not give a price yet. A 10-Q that counts shares in millions gives a rounded number, shown as "about". Shares withheld for employees' taxes are not in this table. A month that no 10-Q table gives, or that this page could not read with confidence, is not shown.
What the 10-Ks show for each CEO's years
Each CEO's years · the CEO of each fiscal year as named in the proxy's pay versus performance table
Matthew Gline
- Operating cash flow
- -$3.2B
- Capital spending
- $26.9M
- Buybacks
- $1.3B
- Stock-based pay
- $1.1B
- Diluted shares since FY2022
- +3.6%
- Revenue since FY2022
- -85%
- CEO pay (reported)
- $216.1M
Sources
The cash flow statement, dividends per share and diluted share count in each 10-K's XBRL; Part II Item 2 of each 10-Q for monthly buybacks; offering prospectuses (S-3, 424B) for new shares; Form D data sets for private raises.
Also
CEO pay: what the CEO was paid over the same years.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ROIV/export.csv") into a cell.